Log in

NYSE:PENPenumbra Stock Price, Forecast & News

$193.98
+2.81 (+1.47 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$191.31
Now: $193.98
$194.18
50-Day Range
$166.88
MA: $176.05
$191.26
52-Week Range
$121.80
Now: $193.98
$194.93
Volume186,934 shs
Average Volume301,060 shs
Market Capitalization$6.80 billion
P/E Ratio177.96
Dividend YieldN/A
Beta0.64
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More
Penumbra logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.27 per share
Book Value$13.91 per share

Profitability

Net Income$48.46 million

Miscellaneous

Employees2,700
Market Cap$6.80 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PEN stock has increased by 9.7% and is now trading at $193.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Penumbra?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Penumbra.

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.04 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.10 by $0.06. The firm had revenue of $137.33 million for the quarter, compared to analyst estimates of $136.28 million. Penumbra had a return on equity of 5.72% and a net margin of 7.04%. The company's revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.23 EPS. View Penumbra's earnings history.

What price target have analysts set for PEN?

5 Wall Street analysts have issued twelve-month price objectives for Penumbra's stock. Their forecasts range from $180.00 to $214.00. On average, they anticipate Penumbra's stock price to reach $194.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Penumbra.

Has Penumbra been receiving favorable news coverage?

Media coverage about PEN stock has been trending negative on Thursday, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Penumbra earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Penumbra.

Are investors shorting Penumbra?

Penumbra saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 2,800,000 shares, a decline of 8.2% from the June 15th total of 3,050,000 shares. Based on an average daily trading volume, of 259,500 shares, the short-interest ratio is currently 10.8 days. Approximately 8.4% of the company's stock are short sold. View Penumbra's Current Options Chain.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), AbbVie (ABBV), DexCom (DXCM), Intuitive Surgical (ISRG), Medtronic (MDT), Boeing (BA), salesforce.com (CRM) and Gilead Sciences (GILD).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.02%) and Diversified Trust Co (0.01%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View institutional ownership trends for Penumbra.

Which major investors are buying Penumbra stock?

PEN stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Diversified Trust Co. View insider buying and selling activity for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $193.98.

How big of a company is Penumbra?

Penumbra has a market capitalization of $6.80 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.